Overcoming resistance in a BRAF V600E–mutant adenocarcinoma of the lung

T. Schmid, M. Buess


We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib–trametinib can overcome vemurafenib resistance in a BRAF V600E–mutated adenocarcinoma of the lung.


Adenocarcinoma; BRAF; MEK; targeted therapy; acquired resistance; non-small-cell lung cancer; dabrafenib; trametinib

Full Text:


DOI: http://dx.doi.org/10.3747/co.25.3936

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)